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Abstract
Poxviruses include medically important human pathogens, yet little is known about the specific cellular factors essential for
their replication. To identify genes essential for poxvirus infection, we used high-throughput RNA interference to screen the
Drosophila kinome for factors required for vaccinia infection. We identified seven genes including the three subunits of
AMPK as promoting vaccinia infection. AMPK not only facilitated infection in insect cells, but also in mammalian cells.
Moreover, we found that AMPK is required for macropinocytosis, a major endocytic entry pathway for vaccinia.
Furthermore, we show that AMPK contributes to other virus-independent actin-dependent processes including lamellipodia
formation and wound healing, independent of the known AMPK activators LKB1 and CaMKK. Therefore, AMPK plays a highly
conserved role in poxvirus infection and actin dynamics independent of its role as an energy regulator.
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Introduction
In order to successfully infect cells, viruses must remodel the
cellular environment to allow for the reallocation of resources to
viral production. Poxviruses are large double stranded (ds) DNA
viruses that have a sophisticated lifecycle characterized by a
number of temporally regulated steps. Vaccinia virus is the
prototypical poxvirus, was used as the vaccine to eradicate
smallpox, and has been the most thoroughly characterized [1].
To initiate infection, vaccinia first binds, enters cells, uncoats, and
expresses early gene products. Next, genomic DNA replication
occurs, followed by intermediate and late gene expression.
Assembly, maturation, and virus release completes the cycle.
Although poxviruses encode a large number of genes (.200),
they remain obligate intracellular pathogens and require a
multitude of activities hijacked from their host cell. While many
viral factors required for various steps in the vaccinia lifecycle
have been described, the specific host factor contribution is less
clear.
In particular, an early step in the infection cycle involves cell
penetration. This step is critical for the initial establishment of
infection, and also presents a good target for anti-viral
therapeutics [2]. Different families of viruses have developed
diverse strategies for entering cells; some fuse at the plasma
membrane, while others co-opt one of the many cellular
endocytic routes [3]. Studies have demonstrated that macro-
pinocytosis is an important endocytic route of vaccinia entry [4].
Generally, macropinocytosis is a nonselective route for bulk fluid-
phase uptake and is not constitutively active, but is induced by
growth factors, and also by some pathogens including vaccinia [5]
[6]. This active endocytic process induces extensive actin
cytoskeletal rearrangement, leading to membrane ruffling,
lamellipodia formation, and the internalization of extracellular
fluid and membrane. Consistent with this, vaccinia entry is
dependent upon modulation of the actin cytoskeleton, and
initiates macropinocytosis by inducing dramatic actin-rich
microvilli protrusions followed by global myosin II-dependent
blebbing, thereby promoting virus uptake [4] [7]. Induction
triggers the activation of receptor tyrosine kinases (RTKs) which
activate complex signaling cascades leading to the induction of
these actin extensions which extend the plasma membrane
allowing fluid-phase capture. This process involves signaling
cascades that converge on members of the Ras superfamily of
GTPases in particular, Rab5 and Rac1 [6] [8]. Rac1 contributes
to a number of cellular processes that require extensive actin
dynamics, and its signaling is carefully regulated by several
guanine exchange factors as well as by crosstalk with other Rho
family GTPases [9] [10] [11]. Again, as for growth factor
dependent macropinocytosis, vaccinia-induced uptake is depen-
dent upon Rac1 [4] [7]. Additional kinases such as p21-activated
kinase (PAK1) are then activated along with actin-associated
proteins that lead to large-scale actin rearrangements, lipid
modifications, and ultimately macropinosome formation [4] [5].
While some specific kinase families have been implicated in
macropinocytosis (e.g., protein kinase C (PKC), serine/threonine
kinases, tyrosine kinases, and phosphatidylinositol kinases) [5],
many of the specific factors have not been identified, and in some
cases the specific role of factors such as PKC, is not well
PLoS Pathogens | www.plospathogens.org 1 June 2010 | Volume 6 | Issue 6 | e1000954understood. Therefore, there are many additional cellular
signaling factors remaining to be identified for this complicated
uptake mechanism and thus, for vaccinia entry.
To take an unbiased systematic approach toward the identifi-
cation of these cellular factors, we developed a system using the
model organism Drosophila to perform a high-throughput RNA
interference (RNAi) screen for cellular kinases and phosphatases
required for early steps in vaccinia infection. The Drosophila system
is particularly amenable to this approach for a number of reasons
including: reduced redundancy in the genome, high conservation
with mammalian systems, efficient RNAi, and previous success
with this system to identify cellular factors required for viral
infection [12] [13]. This Drosophila system is permissive to early
steps in the vaccinia infection cycle allowing us to specifically
dissect the role of cellular factors involved in the infectious entry
process.
Using this system, we identified seven genes that contribute to
vaccinia infection, including the three subunits of the AMP-
activated kinase (AMPK) complex, the master energy sensor of the
cell. Importantly, the requirement for AMPK in vaccinia infection
is conserved in mammalian cells, and is specifically required for
vaccinia-induced macropinocytic entry. Further characterization
led to the discovery that AMPK controls a variety of virus-
independent actin-dependent processes including lamellipodia
formation and cell migration. Altogether, we found a new role
for AMPK in actin dynamics.
Results
Vaccinia infection in Drosophila cells
Since vaccinia infection of Drosophila cells has not been reported,
we first characterized the course of infection in Drosophila cells.
Using a reporter virus expressing Beta-galactosidase (B-gal) under
the control of an early/late promoter which is active during all
stages of vaccinia infection, we found that vaccinia infection is
dose-dependent with maximal expression at 48 hours post
infection (hpi) (Figure S1). Next, we infected Drosophila cells using
reporter viruses that express B-gal under the control of temporally
regulated vaccinia promoters that are active during different
phases of the virus replication cycle. We found that Drosophila cells
were efficiently infected as measured by the production of B-gal
from an early/late promoter (p 7.5) or by the production of E3L
protein, a vaccinia gene product expressed early in infection, while
there was very little expression of B-gal from either an
intermediate promoter (G8R), or a late promoter (p11)
(Figure 1A). Consistent with these findings, we have been unable
to detect vaccinia DNA replication (data not shown) suggesting a
block to infection following early protein synthesis. These findings
demonstrate that while vaccinia is unable to complete all stages of
the lifecycle in Drosophila cells, entry and early expression occur,
providing a model system to study the host factor requirements of
vaccinia entry.
Previous studies have shown that efficient vaccinia entry is
dependent upon the endocytic route of macropinocytosis [4]. In
order to assess whether host requirements for vaccinia entry were
conserved between Drosophila and mammalian cell lines, we tested
whether inhibition of macropinocytosis attenuated infection in
these disparate cell types. To this end, we treated cells with several
known inhibitors of macropinocytosis and vaccinia entry includ-
ing; an actin inhibitor Latrunculin A, phosphoinositide-3-kinase
(PI3K) inhibitor Wortmannin, Na/H antiporter inhibitor EIPA,
and PKC inhibitor Rottlerin [4] [7]. We found that each of these
drugs significantly inhibited vaccinia infection in both human and
Drosophila cells (Figure 1B–C, quantified in Figure S2). These data
show that at least early steps in the viral lifecycle are dependent
upon similar pathways in insect cells allowing us to use this model
to identify additional factors required for vaccinia infection in
mammalian cells.
RNAi screen of Drosophila kinome
In order to systematically probe the requirements for cellular
signaling factors in early vaccinia infection, we developed a
quantitative assay amenable to RNAi using virally encoded B-gal
expression as a measure of early infection. While a non-targeting
negative control dsRNA (GFP) had no effect on the percentage of
infected cells, knock-down of B-gal by RNAi reduced the
percentage of B-gal expressing cells 17-fold, indicating that
vaccinia infection can be quantitatively assayed using this system
(Figure 2A). Moreover, dsRNA targeting the cellular gene Rab5, a
small GTPase required for many endocytic processes including
macropinocytosis [8] also significantly decreased vaccinia infec-
tion, validating that we can identify cell-encoded factors required
for vaccinia infection using this approach (Figure 2A and 2D).
We used this assay to perform an RNAi screen against the
Drosophila kinome to identify novel signaling factors that promote
vaccinia infection (Schematic diagram Figure 2B). This screen
consisted of approximately 440 unique genes (,200 kinases, ,90
phosphatases, and ,150 regulator factors) arrayed onto 384 well
plates (Table S1). Additionally, negative control wells were
included containing either no dsRNA (15 wells) or dsRNA
targeting GFP (28 wells), which is not expressed in this system.
Lastly, 21 positive control wells with dsRNA targeting lacZ were
included (Figure 2B light blue). Drosophila cells were seeded in these
pre-arrayed 384 well plates, incubated for three days to allow
knock down of each targeted gene, and then infected with vaccinia
virus for 48 hours. For the screen, a baseline infection of 10% was
within the linear range and was achieved at a multiplicity of
infection (MOI) of 1.25 (Figure S1C). The plates were fixed and
processed for immunofluorescence using B-gal expression as a
measure of infection, and counter-stained to monitor cell number.
Automated microscopy and image analysis were used to quantify
the percent infection (B-gal
+/Total Nuclei) that was transformed
into Robust Z scores for each plate, and the Robust Z scores of the
2 replicates were plotted against each other (Figure 2B). Positive
candidates were defined as having a Robust Z score of ,22i n
Author Summary
Entry is a vital step in establishing viral infection, providing
a potential therapeutic target. Many viruses co-op one of
the various cellular endocytic routes for entry, making the
host factors that contribute to these processes essential for
efficient infection. In particular, vaccinia, the prototypical
poxvirus, takes advantage of macropinocytosis for efficient
uptake. To identify the signaling factors required for entry
of vaccinia virus we performed an RNAi screen of the
Drosophila kinome for those kinases and phosphatases
that facilitate infection. We identified seven genes
including the three subunits of AMPK as promoting
infection, and found that AMPK was also required in
mammalian cells for vaccinia infection. Furthermore, we
found that AMPK facilitates vaccinia entry thru its ability to
modulate the actin cytoskeleton and macropinocytosis. In
addition to promoting vaccinia uptake, we found that
AMPK also contributes to other virus-independent but
actin-dependent processes including lamellipodia forma-
tion and cellular motility, indicating a broad cellular role in
regulating actin dynamics.
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genes (2%, orange and pink Figure 2B). In addition to these 8
factors, we identified 20 out of 21 (95%) of the positive control lacZ
dsRNAs (Figure 2B light blue and Table S1) and none of the 43
negative controls (non-targeting dsRNA and empty wells). We also
monitored the toxicity of the dsRNA treatments and found that
none of the 8 genes that inhibited infection were cytotoxic (,25%
decrease in cell number, Table 1). In contrast, we found that while
17 wells reduced cell number by .25% in duplicate screens, none
of these genes also inhibited infection. Therefore, our screen
revealed host factors required for robust infection that are not
required for cell viability. Notably all 8 genes have human
homologs (Table 1), including all 3 subunits of the AMP-activated
kinase (AMPK) complex (SNF1A (AMPKa), SNF4Agamma
(AMPKc) and alicorn (AMPKb)) (Figure 2B pink), a heterotri-
meric complex involved in maintaining cellular energy homeosta-
sis. RNAi resulted in ,3-fold reduction in vaccinia infection when
AMPK was depleted (Figure 2C).
Non-overlapping secondary dsRNAs were generated for each of
the 8 genes and were tested to confirm the role of each of these
genes in vaccinia infection. Seven of the genes validated (88%).
Importantly, among the genes that validated were those encoding
the three subunits of the AMPK complex (Figure 2D, Figure S3
and Table 1). Moreover, RT-PCR confirmed that AMPKa was
depleted by dsRNA treatment against AMPKa (Figure S4A).
Furthermore, we found that loss of AMPKa or AMPKc also led to
a defect in early viral mRNA accumulation compared to control
(Figure 2E), suggesting that AMPK is required upstream of viral
mRNA production in Drosophila, perhaps at the stage of entry.
AMPK promotes vaccinia infection in mammalian cells
AMPK is an important sensor of intracellular energy that is
conserved in eukaryotes ranging from yeast to humans [14]. While
Drosophila encodes only one copy of each AMPK subunit,
mammals have multiple isoforms of each subunit encoded by
several distinct genes (a1, a2, b1, b2, c1, c2, c3) which can
Figure 1. Vaccinia virus undergoes entry in Drosophila cells. A. Drosophila cells were infected with three different recombinant vaccinia viruses
expressing B-gal driven by an early/late (p7.5), intermediate (G8R), or late (p11) vaccinia promoter. Each virus expresses E3L protein from an
endogenous early promoter. After 48 hours, infection levels were assessed using B-gal or E3L-specific antibodies. B–C. Vaccinia infection is
dependent upon known mediators of macropinocytosis. B. Human U2OS cells were pretreated with: Latrunculin A, Wortmannin, and Rottlerin at
5 mM; EIPA at 12.5 mM for 1 hour and challenged with vaccinia (MOI=10) for 8 hours. C. Drosophila DL1 cells were treated with: Latrunculin A,
Wortmannin, and Rottlerin at 5 mM; EIPA at 50 mM for 1 hour and challenged with vaccinia (MOI=20) for 24 hours. Cells were fixed and processed for
immunofluorescence using E3L expression (green) as a marker for infection, and Hoescht 33342 (blue) to visualize nuclei. Percent infection is the
average of four images in a representative of three experiments.
doi:10.1371/journal.ppat.1000954.g001
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lack of redundancy in Drosophila allowed our identification of
AMPK by single gene RNAi. We used this Drosophila system as a
tool to identify novel host factors that contribute to vaccinia
infection, but since Drosophila is not a natural host, we were
interested in determining the role of AMPK in a more biologically
relevant context.
To investigate the role of AMPK in vaccinia virus infection of
mammalian cells, we took advantage of mouse embryonic fibroblasts
(MEFs) that are genetically altered and null for both AMPKa
subunits, AMPKa1a n dA M P K a2( A M P K a1/AMPKa2
2/2)
and verified the lack of these proteins by immunoblot analyses
(Figure S5) [16] [17] [18]. These cell lines divide and grow
indistinguishably from their sibling control AMPKa1/AMPKa2
+/+
cells (wild type) (data not shown). We challenged either the
AMPKa1/AMPKa2
2/2 cells or their sibling control wild type cells
with vaccinia virus and measured infection using a plaque assay.
This revealed a 20-fold decrease in plaque number and a 15-fold
Figure 2. High-content RNAi screen identifies cellular factors required for vaccinia infection. A. Cells were pre-treated with the indicated
dsRNAs and infected with E/L (p7.5) B-gal vaccinia at MOI of 1.25 for 48 hours. Percentage of infected cells is calculated from ((B-gal
+, green)/(nuclei,
blue)). B. Schematic of high-throughput RNAi screening. Cells were plated in 384 well plates arrayed with gene-specific dsRNA targeted against the
Drosophila kinome. After three days, the cells were infected with E/L B-gal vaccinia at MOI=1.25 for two days and then processed for
immunofluorescence. Automated image analysis was used to determine the percentage of infected cells and used to identify the positive candidates
(Z,22 in duplicate). Candidates in light blue represent the B-gal-depleted positive controls, and those in pink represent the three subunits of the
heterotrimeric AMPK complex. Other candidates are indicated in orange. C. Examples of primary screen data including AMPK components that when
depleted resulted in a significant decrease in the percentage of B-gal-positive cells. D. Independent dsRNAs against each of the three AMPK subunits:
AMPKa (SNF1A), AMPKb (alicorn) and AMPKc (SNF4Agamma). RNAi was performed and cells were infected at an MOI=5. Percent infection was
measured and the mean +SD is shown; * indicates p,0.05 compared to control in three independent experiments. E. Northern blot analysis was
performed on RNA extracted from cell lysates pretreated with dsRNA targeting the indicated genes and probed for B-gal, and a loading control RpS6.
doi:10.1371/journal.ppat.1000954.g002
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2/2 compared to
wild type cells (Figure 3A–C). The requirement for AMPK was
also observed for the closely related poxvirus, cowpox virus
(Figure 3D, quantified in Figure S6). These decreases in infectivity
were specific for poxviruses and not simply due to a decrease in
overall cell health since several unrelated RNA viruses, including
Vesicular Stomatitis virus (VSV) grew as well in the AMPK
deficient MEFs compared to wild type (Figure S7 and data not
shown). This suggests that AMPK deficient cells are capable of
supporting all stages of virus infection; including at least some
forms of endocytosis and endosomal trafficking since VSV enters
cells through clathrin-mediated endocytosis [19]. Therefore, we
identified a specific requirement for AMPK in poxvirus infection
but not for viral infection generally. In addition to plaque assays
we also monitored vaccinia infection by immunofluorescence,
immunoblot, and Northern blot and found that there was a
significant decrease in vaccinia virus replication in AMPKa1/
AMPKa2
2/2 cells in each assay (Figure S8A–C). This suggests
that AMPK promotes early steps of the vaccinia lifecycle in
mammalian cells as well as Drosophila. Finally, to verify that the
requirement for AMPK was not MEF-specific we tested whether
inhibition of AMPK in the human osteosarcoma cell line U2OS
attenuated vaccinia infection using two approaches. First, we pre-
treated U2OS cells with the AMPK inhibitor Compound C or
vehicle and challenged these cells with vaccinia [20]. Again, we
found that inhibition of AMPK attenuated infection (Figure 4A,
B). Next, we depleted AMPKa1, AMPKa2, or both AMPKa1
and AMPKa2 using siRNAs and observed a decrease in vaccinia
infection (Figure S9A, B, Text S1). We confirmed knock-down by
immunoblot (Figure S9C). Together, these data show that
vaccinia infection is dependent upon AMPK for infection across
disparate cell types including Drosophila, human and mouse.
Vaccinia infection activates AMPK
AMPK is activated through phosphorylation of a threonine
residue on the catalytic a subunit, which can be triggered by a
variety of stimuli including an increase in the cellular ratio of
AMP/ATP [21] [22] [23] [24] [25] [26]. Since AMPK promotes
vaccinia infection, we tested whether infection activates AMPK.
We used a phospho-specific antibody against AMPKa to measure
AMPK activation. Treatment with 2-deoxyglucose (2DG), a
known activator of AMPK, led to an increase in AMPK
phosphorylation, while little phosphorylation was detected in
untreated controls (Figure 4C). Moreover, we observed an increase
in phospho-AMPKa within 10 minutes of vaccinia infection
(Figure 4C). This increase was not due to changes in total AMPK
levels, and suggests that AMPK becomes activated very early in
vaccinia infection.
Known upstream activators of AMPK are not required for
vaccinia infection
Several upstream kinases have been implicated in AMPK
activation under different conditions. The classic activator of
AMPK is the tumor suppressor LKB1, which activates AMPK in
response to energy deprivation [27] [28]. In Drosophila, LKB1 is
the only described upstream kinase required for AMPK activation
and lkb1 mutants phenocopy ampk mutants [29] [30]. In contrast,
in mammalian systems, LKB1 is the upstream kinase in response
to energy deprivation, while additional upstream kinases, such as
calcium/calmodulin-dependent protein kinase kinase beta
(CaMKKb) have been implicated in AMPK activation under
other conditions [31] [32]. We tested whether LKB1 was required
for vaccinia infection using cells that are null for LKB1 [33] and
complemented with either vector alone (LKB1
2/2; Vec), or an
LKB1 cDNA (LKB1
2/2; LKB1) (Figure S10) and found that loss
of LKB1 had no effect on vaccinia infection in mammalian cells
(Figure 4D). Likewise, using RNAi to deplete LKB1 in Drosophila
cells, we found that it was dispensable for infection by
immunofluorescence (Figure 4E) and Northern blot (Figure 4F).
RT-PCR analysis validated that LKB1 was indeed knocked down
in Drosophila cells (Figure S4B). We also tested whether CaMKK,
the other well-established AMPK activator in mammalian systems,
was required for vaccinia infection. To this end, we pre-treated
U2OS cells with the CaMKK inhibitor STO609 prior to
infection, and found no effect on vaccinia infection with doses
up to 5 mg/ml (Figure 4A, B). Taken together, these data show
that vaccinia infection is AMPK-dependent but LKB1 and
CaMKK-independent.
AMPK promotes vaccinia entry
Given that loss of AMPK led to a decrease in both viral mRNA
and protein production (Figure 2, Figure S8), we tested whether
AMPK was required for efficient virus entry. We monitored viral
entry into wild type or AMPKa1/AMPKa2
2/2 MEFs using a
fluorescence-based assay. We prebound virus to the cells, and then
allowed infection to proceed for one hour. Incoming virus particles
Table 1. Candidate genes identified and validated.
% infection Robust Z score Nuclei fold change Validated?
Drosophila Gene Human Gene Screen #1 Screen #2 Screen #1 Screen #2 Screen #1 Screen #2
median 3.9 7 1 1
B-gal 0.9 1.2 217.5 210.8 1 1
SNF1A PRKAA2 1.7 2.8 24.5 25.4 0.8 1 Yes
SNF4Agamma PRKAG2 1.1 1.9 23.9 27 1 0.9 Yes
alicorn PRKAB1 0.3 4.2 23.9 23.4 1 1.1 Yes
Fab1 PIKfyve 3.4 4.5 22.3 22.2 1 1 Yes
Pi3K68D PIK3C2A 2.4 3.3 23.8 23.9 1.1 1.1 Yes
Stam STAM 3.3 4.5 22.1 22.5 1 1.1 Yes
CG9311 PTPN23 3.1 2.5 23.8 25.7 1 0.9 Yes
Strn-Mlck MYLK 0.6 4.8 22.5 22.8 1 1.1 No
doi:10.1371/journal.ppat.1000954.t001
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bound viral surface protein (Figure 5A). Deconvolution of Z stacks
was used to visualize vaccinia inside of cells (Figure 5A, XZ view).
Quantification revealed a ,3-fold reduction in the number of
AMPK mutant cells that internalized virus (Figure 5B). These data
show that AMPK promotes infection at the stage of entry,
although we have not ruled out that virus binding could also be
affected by lack of AMPK.
We were also interested in whether AMPK played a role in
vaccinia infection downstream of entry. First, we monitored both
early and late gene expression and found that while the percentage
of cells expressing an early protein (E3L) or a late protein (L1R)
was reduced in AMPKa1/AMPKa2
2/2 MEFs compared to wild
type, 100% of the cells that expressed early genes also expressed
late genes, indicating no further block to replication (Figure S11A).
We also measured the infectivity of virus produced from
AMPKa1/AMPKa2
2/2 MEFs. We found a ,3-fold decrease
in virus titer produced from AMPKa1/AMPKa2
2/2 MEFs
compared to wild type (Figure S11B) which is similar to the
decrease in viral entry (Figure 5B). These data suggest that while
fewer AMPK deficient cells produce virus, the vaccinia released
from these cells is as infectious as virus produced from wild type
cells. Therefore, while AMPK is important for entry, it is
dispensable for later steps in the viral lifecycle.
AMPK is required for vaccinia induced macropinocytosis
Previous studies established that a major entry route for vaccinia
is macropinocytosis, which is required for and induced by vaccinia
infection [4]. Since we observed a defect in viral entry in the
AMPK mutant cells (Figure 5), and that inhibitors of macro-
pinocytosis attenuated vaccinia infection (Figure 1), we tested
whether AMPK plays a role in vaccinia-induced macropinocy-
tosis. Macropinocytosis can be directly monitored by fluorescently
labeled dextran uptake [34]. Neither wild type nor AMPKa1/
AMPKa2
2/2 MEFs efficiently endocytosed dextran under
resting conditions (Figure 6A). However, upon vaccinia infection,
macropinocytosis was dramatically induced in wild type MEFs as
measured by an increase in dextran uptake into the cell. In
contrast to the large number of dextran punctae observed in the
infected wild type MEFs, AMPKa1/AMPKa2
2/2 MEFs did not
efficiently take up the dextran in the presence of virus (Figure 6A).
We quantified the level of vaccinia-induced macropinocytosis in
the wild type versus AMPK deficient cells and found an
approximately five-fold reduction in the percentage of cells
undergoing macropinocytosis (Figure 6B).
Furthermore, we found a decrease in vaccinia-induced dextran
uptake in human U2OS cells pretreated with Compound C
compared to vehicle control (Figure 6C). Quantification revealed
an approximately five-fold decrease in the percentage of U2OS
cells undergoing vaccinia-induced macropinocytosis when AMPK
is inhibited (Figure 6D). Together, these data show that virus-
induced macropinocytosis is dependent upon AMPK in disparate
cell types and hosts.
In contrast to this dependence of macropinocytosis on AMPK,
there was no defect in transferrin uptake in AMPKa1/AMPKa2
2/2
MEFs (Figure S12, Text S1), indicating that receptor-mediated
endocytosis is not controlled by AMPK. This is consistent
with our observation that VSV infection is not attenuated
in AMPKa1/AMPKa2
2/2 MEFs as VSV enters cells
by receptor-mediated endocytosis and not macropinocytosis
(Figure S7).
AMPK promotes lamellipodia formation
One of the early steps in macropinocytosis involves extensive
actin remodeling characterized by membrane ruffling and
lamellipodia formation. We were interested in determining
whether AMPK was required for this early step in the
macropinocytic pathway, and whether the requirement for AMPK
in macropinocytosis was vaccinia-dependent or if AMPK was
required more generally for actin remodeling. Therefore, to test
whether AMPK controlled actin-dependent remodeling indepen-
dent of viral infection, we treated cells with phorbol myristic acid
(PMA), which induces cells to undergo high levels of actin-
mediated ruffling and lamellipodia formation; this is dependent on
Rac1, a small Rho family GTPase that is also required for
macropinocytosis and vaccinia infection [7] [35] [36] [37].
Dramatic lamellipodia formation, seen as thick bands of actin at
the cell periphery, were observed in wild type MEFs stimulated
with PMA, but abrogated in AMPK-deficient cells (Figure 7A,
arrows). We also monitored PMA-induced ruffling using live cell
Figure 3. AMPKa promotes poxvirus infection in mammalian
cells. A. Vaccinia virus plaque assays were performed with wild type or
AMPKa1/AMPKa2
2/2 MEFs. Representative data from the10
25 dilution
of virus is shown. B. Quantification of plaques from A. presented as the
normalized mean +SD of wild type plaques from four experiments;
* indicates p,0.05. C. The diameter of 30 representative plaques in
each duplicate well from A. was used to calculate the average plaque
area, which is displayed as the normalized mean +SD in triplicate
experiments; * indicates p,0.05. D. Cowpox virus plaque assays were
performed with wild type or AMPKa1/AMPKa2
2/2 MEFs. Representa-
tive data from the10
25 dilution of virus is shown.
doi:10.1371/journal.ppat.1000954.g003
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MEFs (Videos S1, S2, Text S1).
In addition, we monitored the localization of Rac1 during
PMA-induced lamellipodia formation in the wild type and AMPK
deficient cells and found that both Rac1 re-localization and actin
mobilization are defective in AMPK deficient cells (Figure 7B)
suggesting that the defect is upstream of or parallel to Rac1
activation.
While our studies identified AMPK as a critical kinase required
for vaccinia infection and actin dynamics, we found that LKB1
was dispensable for infection. This led us to test whether actin-
dependent lamellipodia formation and ruffling was also LKB1-
independent. We found that there was no defect in PMA-induced
lamellipodia and ruffling in LKB1-deficient cells (Figure 7C,
arrows). This was not unexpected since HeLa cells, a cell type
routinely used for studies on actin dynamics, are mutant for LKB1,
and can still undergo lamellipodia formation, and macropinocy-
tosis [4] [38] [39] [40]. Therefore, we found that the actin
remodeling activity of AMPK is independent of LKB1.
AMPK promotes cellular motility
Since extensive actin remodeling and Rac1 membrane
localization are required for lamellipodia formation, macropino-
Figure 4. Vaccinia infection induces AMPK activation, and is independent of LKB1 and CaMKK. A. Human U2OS cells were pre-treated
with vehicle, Compound C (1–5 mM), or STO609 (1–5 mg/mL) and then infected with vaccinia (MOI=10) for 8 hours (E3L, green; nuclei, blue). A
representative of 3 experiments is shown. B. Percent infection of A was measured and the mean +SD is shown; * indicates p,0.05 compared to
control in three independent experiments. C. Cells were pretreated with vaccinia virus (MOI=20) at 16uC for 1 hour, and then infected at 37uCo r
treated with 2DG, a known inducer of AMPK phosphorylation. Lysates were collected at the indicated time points post treatment and assayed by
immunoblot for phospho-AMPK. A representative of 3 experiments is shown. D. LKB1
2/2 MEFs were complemented with a vector control (LKB1
2/2;
Vec) or FLAG-LKB1 cDNA (LKB1
2/2; LKB1) and subsequently infected with vaccinia at the indicated MOI for 8 hours, and processed for
immunofluorescence. Percent infection was quantified using automated image analysis. A representative of two experiments is shown. E. RNAi
against LKB1 in Drosophila cells had no effect on infectivity compared to RNAi against negative control luciferase as measured by
immunofluorescence. F. LKB1 knock down in Drosophila has no effect on vaccinia early mRNA levels as measured by Northern blot. Cells were
pretreated with dsRNAs against negative control luciferase, positive controls E3L (viral) and Rab5 (cellular), as well as AMPKa and LKB1 and probed as
indicated.
doi:10.1371/journal.ppat.1000954.g004
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whether AMPK was required for another Rac1-dependent actin-
dependent process namely in vitro wound healing [41]. For these
studies, we created wounds in a confluent monolayer of either
wild type or AMPKa1/AMPKa2
2/2 MEFs by scratching the
surface, and monitored wound closure over time. Using this assay
we found that there was a significant delay in the migration of
AMPK-deficient MEFs into the wound compared to wild type
cells (Figure 7D, E). While the wound was completely healed
24 hours after wounding in wild type cells, a sizable gap in the
monolayer was still present in AMPK deficient cells, indicating a
delay in wound healing and reduced motility. During this motile
state, cells undergo a dramatic change in shape, with lamellipodia
forming at the leading edge directing cell migration to close the
wound. We observed the formation of lamellipodia in the WT
MEFs at the edge of the wound while AMPK mutant MEFs did
not polarize (Figure S13). Consistent with our observations that
the role for AMPK in actin dynamics is LKB1-independent, we
found that wound healing is unaffected by the loss of LKB1
(Figure S14).
Discussion
Cell penetration is a critically important step in viral infection,
and one that is generally driven by cellular factors and signaling
pathways. First, viruses must attach to the cell surface and bind to
the viral entry receptor, which often initiates signaling within the
cell. Next, viruses must fuse or penetrate the cellular membrane
either at the cell surface, or in many cases, within intracellular
compartments by taking advantage of the endogenous endocytic
machinery. Since there is an array of different endocytic
mechanisms, there is great diversity in the strategies used by
viruses for entry. Therefore, studying virus entry has increased our
understanding not only of viral infection, but also of the normal
cellular processes of endocytosis [6].
To further dissect the cellular signaling requirements of vaccinia
entry, we developed an unbiased loss-of-function screening
platform in Drosophila cells, and identified seven cellular factors
required for vaccinia infection. Amongst the genes were all three
subunits of AMPK, implicating the entire complex in vaccinia
infection. Further studies showed that in addition to its role in
Drosophila, AMPK is also required in murine and human cells for
poxvirus infection at the stage of entry. Moreover, AMPK
becomes rapidly activated upon infection with vaccinia, suggesting
that virus-induced signals converge on this complex to facilitate
entry.
Studies indicate that vaccinia virus can enter cells through
multiple routes via as of yet unidentified receptor(s). Studies
suggest that virus particles can fuse either at the plasma membrane
or from within endosomal compartments, dependent on cell type
and virus strain [42] [43] [44] [45] [46]. Importantly, a major
endocytic pathway for vaccinia entry has recently been described
as macropinocytosis [4] [47]. Our data as well as previous reports
support the idea that vaccinia uses macropinocytosis for entry, but
not exclusively. We and others have shown partial inhibition of
vaccinia infection using a variety of drugs that are well-established
inhibitors of macropinocytosis [4] [7]. However, in no case was
vaccinia entry completely dependent upon macropinocytosis for
infection, demonstrating that the virus can use alternative routes
for entry. Nevertheless, macropinocytosis is required for efficient
entry across broad cell types suggesting that inhibition of this
pathway may attenuate infection sufficiently to allow for immune-
mediated clearance of the infection.
The process of macropinocytosis drives non-specific uptake of
extracellular fluid, large portions of the plasma membrane, as well
as large particles. Macropinosomes, unlike coated vesicles, are
Figure 5. AMPK promotes vaccinia entry. A. Wild type or AMPKa1/AMPKa2
2/2 MEFs were either infected or mock-infected with vaccinia, and
the L1R membrane protein (red) was monitored to visualize incoming virus. Nuclei (blue) and actin (phalloidin (green)) were also stained. Images are
presented as max projection along with XZ insets. Representative images of triplicate experiments are shown. B. The percentage of cells undergoing
vaccinia entry was quantified (n.30 for each condition).
doi:10.1371/journal.ppat.1000954.g005
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0.2–10 mm in diameter, sufficient to accommodate the large size of
vaccinia virus particles (,0.3 mm) [5] [48]. Classic induction of
macropinocytosis by growth factor receptor signaling stimulates
ruffles, or sheet-like extensions of the plasma membrane, formed
by assembly of actin filaments beneath the plasma membrane that
form cups that contract and close to form macropinosomes [5].
This process is driven by signaling events initiated at the plasma
membrane and are thought to involve a number of kinase families
including phosphatidylinositol 5-kinases (PI5K), PI3K, PKC,
serine/threonine kinases, and receptor tyrosine kinases. In
addition, as many different inducers of macropinocytosis have
been identified, there are likely multiple pathways that converge
on the activation of macropinocytosis, adding to the complexity of
this cell biological pathway [5]. While several specific kinases, such
as PAK1, and LIM kinase have well described roles in
macropinocytosis [49] [50], there is much that remains unclear.
Here, we have found a role for an additional kinase, AMPK, in
promoting vaccinia entry through its role in macropinocytosis. We
have found that AMPK deficiency attenuates vaccinia infection,
concomitant with reduced entry and fluid-phase uptake, support-
ing an important role for AMPK in vaccinia-induced macro-
pinocytic entry.
The process of macropinocytosis involves several steps including
extensive actin-mediated membrane ruffling, cup formation, and
finally cup closure, which requires the fusion of plasma
membranes to close off the macropinosome, followed by fission
to separate the macropinosome from the plasma membrane [5].
We discovered that AMPK is required for the formation of
lamellipodia and affects the recruitment of Rac1 to the cell
periphery, suggesting that the role of AMPK in macropinocytosis
lies in the initial rearrangement and reorganization of the actin
cytoskeleton.
While we have shown that AMPK contributes to actin
remodeling during vaccinia-induced macropinocytosis, we also
found that AMPK plays a role in other virus-independent
remodeling processes including cell migration. During this process,
forward movement is driven by the extension of a leading edge
protrusion or lamellipodium, followed by contraction at the rear.
This protrusive force is generated by localized polymerization of
actin mediated by Rac1 [51]. In addition to its role in controlling
ruffling upstream of macropinocytosis, we found AMPK also has
Figure 6. AMPK is required for vaccinia-induced macropinocytosis. Fluid phase dextran uptake assays were performed in the presence or
absence of virus. A. Wild type and AMPKa1/AMPKa2
2/2 MEFs were either infected or mock-infected and treated with FITC-dextran (red), processed
for microscopy, and stained to visualize actin (phalloidin (green)) and nuclei (Hoescht 33342 (blue)). Representative images from triplicate
experiments are shown. B. The percentage of MEFs with dextran punctae was quantified from three independent experiments with the mean + SD
shown; * p,0.05. C. U2OS cells were treated or mock-treated with the AMPK inhibitor Compound C (10 mM) 1 hour prior to addition of vaccinia.
Texas Red-dextran (red) was added and processed as above. D. The percentage of U2OS cells with dextran punctae was quantified from three
independent experiments with the mean +/2 SD shown; *p,0.05.
doi:10.1371/journal.ppat.1000954.g006
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demonstrating a broad role in Rac1-dependent actin modulation.
Previously, Rac1 has been implicated in nitric oxide production
and glucose uptake downstream of AMPK [52] [53]. This role for
AMPK and Rac1 in glucose uptake via the translocation of the
major insulin-responsive glucose transporter GLUT-4 is quite
interesting because this may provide a direct link between
AMPK’s role in energy homeostasis and the cytoskeleton [54]
[55] [56].
While the best understood role of AMPK is its role in
metabolism, recent evidence suggests this kinase also has a crucial
role in regulating cell structure and polarity through engagement
with the actin cytoskeleton. In Drosophila, loss of AMPK leads to
defects in mitotic division and epithelial cell polarity accompanied
by disruption of the actin cytoskeleton [29]. In some mammalian
epithelial cell lines, AMPK activation leads to polarization
characterized by the formation of an actin brush-border or tight
junction assembly [29] [57] [58]. Additionally, AMPK activation
can induce astrocyte stellation, and actin stress fiber disassembly
[59]. Finally, studies using Compound C and AMPK activators
linked AMPK to macropinocytic uptake of albumin in murine
macrophages [60]. Taken together with our new data, this
accumulating evidence suggests a broad and conserved role for
AMPK in a variety of cellular processes that require actin
cytoskeletal rearrangements.
The precise signaling events that lead to these AMPK-
dependent cytoskeletal changes remain unclear. Several upstream
kinases have been shown to activate AMPK under different
stimuli. The best studied of these is the tumor suppressor LKB1
which activates AMPK in response to changes in cellular energy
levels [27] [28]. Additionally, AMPK can be activated in response
to changes in intracellular calcium levels by CaMKKb, and
further evidence suggests that TGFb-activating kinase (TAK1)
may serve as a third upstream activator [31] [32] [61]. Previous
studies demonstrated that LKB1 is an important mediator of cell
polarity at least in part through signaling to AMPK, and has been
shown to drive actin brush border formation, and the translocation
of apical and basal markers during the establishment of polarity
[29] [30] [57] [58] [62]. We found that at least some AMPK-
dependent cytoskeletal changes are independent of LKB1 and
CaMKK including lamellipodia formation, macropinocytosis and
wound healing. These different actin-dependent outcomes could
be controlled by the unique downstream Rho GTPase family
members that may become activated by AMPK depending on the
Figure 7. AMPK is required for actin-dependent membrane ruffling and wound healing independent of LKB1. A. Cells were treated
with vehicle or PMA and stained with phalloidin (actin, green) and Hoescht 33342 (nuclei, blue). Arrows indicate lamellipodia. Representative images
from triplicate experiments are shown. B. Cells were treated with PMA and stained with phalloidin (actin, green), anti-Rac1 (red) and Hoescht 33342
(nuclei, blue). Representative images from triplicate experiments are shown. C. MEFs null for LKB1 (LKB
2/2; Vec) or rescued (LKB1
2/2; LKB1) were
treated with PMA or vehicle and stained as in A. Arrows indicate lamellipodia. Representative images from triplicate experiments are shown. D.A
scratch was made in a confluent monolayer of wild type or AMPKa1/AMPKa2
2/2 MEFs, and monitored over time for closure. Representative images
from triplicate experiments are shown immediately after wounding (T=0) and after 20 hours (T=20). E. Reduction in wound width is quantified over
time. Data are normalized to initial would width at T=0, and presented as means of three independent experiments with four wounds per set;
* indicates p,0.05 in each experiment. Moreover, the rate of wound healing is reduced in AMPK mutants by ANOVA (p,0.001).
doi:10.1371/journal.ppat.1000954.g007
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with lamellipodia formation and macropinocytosis) [10] [11].
Study of the Rho family GTPases activated by AMPK under
different stimuli may resolve some of these issues.
In addition to the three subunits of AMPK discovered through
screening the kinome, we identified four other genes that promote
vaccinia infection: Pi3K68D, Fab1, Stam, and CG9311, all of
which have human homologs. Pi3K68D, Fab1, and Stam are
kinases while CG9311 is the only phosphatase identified in the
screen. As kinases are druggable targets, and many known factors
involved in macropinocytosis are kinases, we are particularly
interested in the role of these kinases in vaccinia infection. Both
Pi3K68D (PIK2C2A) and Fab1 (PIP5K3/PIKfyve) have roles in
metabolism of phosphatidylinositol (PtdIns), an important compo-
nent of membrane trafficking, cytoskeletal rearrangements, and
macropinocytosis. In particular, Pi3K68D is a member of the class
II family of PI3Ks that produce PtdIns(3)P downstream of growth
factor stimulation, and can modulate the activity of Rho GTPases
such as Rac1 and Cdc42. Class II PI3Ks have a critical role in
lamellipodia formation and in cell migration, localizing to the
leading edge of migrating cells [63] [64]. Interestingly, class I
PI3K have also been implicated in vaccinia infection, during virus
entry, and also later stages of infection [4] [65] [66]. Fab1, the
PtdIns(3)P 5-kinase that converts PtdIns(3)P into PtdIns(3,5)P2, has
been implicated in fluid-phase uptake, transport, and endosomal
acidification [67] [68]. The third kinase, Stam (STAM, STAM2) is
activated by cytokine and growth factor stimulation, and localizes
to early endosomes, where it is involved in endosomal sorting [69]
[70]. Since these kinases have roles either in trafficking to or from
the plasma membrane, or in cytoskeletal rearrangements, and
have been implicated in processes related to macropinocytosis, it is
quite possible that they also play a direct role vaccinia entry.
Perhaps Pi3K68D is involved in promoting cytoskeletal rear-
rangements that lead to macropinocytosis, while Fab1 and Stam
could be involved sequentially in later entry steps leading to
membrane fusion once a macropinosome has been internalized.
Rearrangements in the actin cytoskeleton are crucial not only
for vaccinia infection, but also for many essential cellular processes
including: cell division, establishment and maintenance of polarity,
cellular motility, and uptake of extracellular fluids, each of which
must be carefully regulated. While these various processes have
different outcomes for the cell, they share several important
signaling components, with AMPK as a central mediator. Further
characterization of AMPK as well as these additional new factors
is required to determine their precise role in vaccinia infection and
whether they interact with AMPK, macropinocytosis, or other
actin-dependent processes. How AMPK activation in response to
different signals leads to these disparate changes in the actin
cytoskeleton, and how these processes fit into the larger network of
AMPK-dependent pathways will drive future studies. Lastly, the
development of more selective AMPK inhibitors or other
inhibitors of macropinocytosis may be useful against poxviruses,
and other viruses that hijack this endocytic route for their entry
mechanism.
Materials and Methods
Cells, antibodies, reagents, and viruses
Drosophila DL1 cells were grown and maintained at 25uCi n
Schneiders Drosophila media supplemented with 10% FBS (JRH)
as described [71]. MEFs, BSC-1 and U2OS cells were
maintained at 37uC in DMEM supplemented with 10% FBS
(Sigma) and 10 mM Hepes. HeLa S3 suspension cells were
maintained in MEM supplemented with 10% FBS and 0.05%
Pluronic. BSC-1 cells were maintained in MEM supplemented
with 10% cosmic calf serum (Hyclone). All media were
additionally supplemented with 100 mg/ml penicillin/streptomy-
cin and 2 mM L-glutamine. LKB1
2/2 MEFs were complement-
ed with MIGR (Vector) or FLAG-LKB1-MIGR (LKB1 cDNA)
and maintained as above. Vaccinia strains vPRA13, vSC8, and
vP30CP77, were grown in HeLa S3 suspension cells supplement-
ed with 2.5% FBS, and tittered on BSC-1 cells as described [72]
[73] [74] [75]. Cowpox Brighton Red and Vesicular Stomatitis
virus (Indiana) were used. Antibodies were obtained from the
following sources: anti-Bgal (Promega and Cappel), anti-E3L (gift
from S. Isaacs) [76], anti-L1R (R180 gift from G. Cohen and R.
Eisenberg), anti-Rac1 (Millipore),and anti-AMPK (Cell Signaling
Technology). Fluorescently labeled secondary antibodies along
with anti-sheep HRP were obtained from Jackson Immunochem-
icals or Invitrogen. All other HRP-conjugated antibodies were
obtained from Amersham. AlexaFluor 488 and 594 phalloidin,
FITC-conjugated dextran, and 594-conjugated Transferrin were
purchased from Invitrogen. Compound C [20] and STO-609
[77] were obtained from Calbiochem. Additional chemicals were
obtained from Sigma.
RNAi and infections
A mini library of dsRNAs generated against Drosophila kinase
and phosphatase genes was obtained from N. Perrimon, and
aliquoted onto 384 well plates at 250 ng dsRNA/384 well [78].
Secondary amplicons and control dsRNA were designed using
SnapDragon and DRSC resources (www.flyrnai.org), and gener-
ated as described [79]. For 384 well assays, 16,000 DL1 cells were
seeded onto 250 ng dsRNA in 10 ml serum free media. One hour
later 20 ml complete media was added, and cells were incubated in
a humid chamber for 3 days. For other experiments, 2,000,000
cells were seeded onto 4 mg of dsRNA/6 well in 1 mL serum free
media. One hour later 2 mL complete media was added. For viral
infections, vaccinia was tittered on BSC-1 cells, and MOIs added
to all cell types are based on pfu/ml measured on BSC-1 cells.
Media was removed and virus was added in 2% serum medium
and incubated at 25uC for Drosophila cells, and 37uC for
mammalian cells. Viral innocula used was adjusted to achieve
,10% infection of Drosophila cells in the primary screen, and
,20% infection in secondary analysis. Level of infection of
mammalian cells varied depending on the assay format. Cells were
processed at the indicated time point post infection.
Viral immunofluorescence
Cells were fixed and processed for immunofluorescence as
previously described at 48 hours post infection for Drosophila cells
and 8 hours post infection in mammalian cells [12]. Briefly, cells
were fixed in 4% formaldehyde/phosphate buffered saline (PBS),
washed twice in PBS/0.1% TritonX-100 (PBST), and blocked in
2% BSA/PBST. Anti-E3L and anti-B-gal primary antibodies were
diluted in block, added to cells, and incubated overnight at 4uC.
Cells were washed three times in PBST, and incubated in
secondary antibody for one hour at room temperature. Cells were
counterstained with Hoescht33342 (Sigma). Plates were imaged at
20X for Drosophila cells and 10X for mammalian cells, capturing
three images per well per wavelength using an automated
microscope (ImageXpress Micro), and quantification was per-
formed using MetaXpress image analysis software. Significance
was determined using a Student T-test.
Screen analysis
Image analysis was used to generate metrics from the
captured images including the number of nuclei and the
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calculated for each site, log-transformed, and the interquartile
range (IQR) was used to calculate a robust Z score for each site
using the following equation: log10 [(%infection-median)/
(IQR*0.74)] [80]. Candidates were identified as positive if the
average robust Z score of all sites in a well was ,22i nt w o
independent replicates.
Immunoblotting, Northern blotting, and RT-PCR
For protein analysis, MEFs were prechilled to 16uC for 10
minutes and then treated with vaccinia (MOI 20) for 1 hour at
16uC to synchronize infection. Cells were incubated at 37uC for 10
or 30 minutes or treated with 10 mM 2DG for 30 minutes. Cells
were then washed briefly in cold PBS and lysed in NP40 lysis
buffer supplemented with protease (Boehringer) and phosphatase
(Sigma) inhibitor cocktails. Samples were separated by SDS-PAGE
and blotted as described [81]. HRP-conjugated secondary
antibodies and Western Lightening Chemiluminescence Reagent
were used for visualization.
For RNA analysis, cells were lysed in Trizol buffer, and RNA
was purified and blotted as previously described with the indicated
probes [12]. RT-PCR was performed using M-MLV reverse
transcriptase on random primed total RNA (Invitrogen). One mL
of the cDNA or a 1:10 dilution was used for PCR amplification.
Plaque assays
Viruses were plaqued on MEF or BSC-1 cells as indicated.
Confluent monolayers were treated with serial dilutions of virus for
two hours, after which the cells were overlayed with agarose
followed by crystal violet staining. Plaque number was determined
manually, and plaque diameter was measured using MetaXpress
software and used to calculate areas.
Vaccinia entry assay
MEFs plated on cover slips were chilled to 16uC for 10 minutes
and then treated with vaccinia (MOI 100) at 16uC for 1 hour.
Unbound virus was removed, and cells were incubated at 37uC for
1 hour, washed three times in cold PBS, and fixed. Cells were
washed in ammonium chloride (50 mM) and PBST and were
stained with anti-L1R and then washed and incubated with
secondary antibody, Hoescht 33342, and phalloidin 488. Cover
slips were mounted and imaged using a 63X objective with a Leica
DMI 4000 B fluorescent microscope. Images were taken as 0.2 um
Z-stacks that were deconvolved using AutoQuant X2 software
using Adaptive PSF with 20 iterations. Images are displayed as
max projections. To quantify, images were randomized and
blindly quantified for virus entry (n.30 for each condition).
Fluid-phase dextran uptake assay
MEFs grown on glass cover slips were chilled to 16uCf o r1 0
minutes and then treated with vaccinia (MOI 200) at 16uCf o r
1 hour. Unbound virus was removed, and FITC-dextran (70 kD,
lysine fixable) was added at 0.5 mg/ml. Cells were incubated at
37uC for 20 minutes, washed twice in PBS, and once in pH 5.5
buffer (0.1 M sodium acetate, 0.05 M NaCl) for 5 minutes. Cells
were fixed and stained with Hoescht 33342 and phalloidin 594.
Cover slips were mounted and imaged using a 63X objective with
a Leica DMI 4000 B fluorescent microscope. Images were
randomized and blindly quantified for the percentage of cells
undergoing macropinocytosis as defined by .20 punctae per cell.
U2OS cells grown on glass cover slips were pretreated with
10 mM Compound C or vehicle for 1 hour and then assayed as
above.
Actin ruffling assay
Cells were grown on glass cover slips and treated with vehicle or
1 mM PMA for 3 hours. For Rac1 localization experiments, cells
were blocked in 8% BSA/PBST for 1 hour. Anti-Rac1 (Millipore)
was added in 1% BSA/PBST overnight at 4uC. Cells were washed
3 times in PBST, and secondary antibodies were added for 1 hour
at room temperature. For all experiments, cells were stained with
Hoescht 33342 and phalloidin 488. Cover slips were mounted and
imaged using a 63X objective with a Leica DMI 4000 B
fluorescent microscope.
Transferrin uptake assay
Cells grown on glass cover slips were chilled to 16uC for 10
minutes and then treated with vaccinia (MOI 100) at 16uC for
1 hour. Unbound virus was removed, and 594-transferrin was
added at 20 mg/ml. Cells were incubated at 37uC for 20 minutes,
washed twice in PBS, and once in 0.1 M sodium acetate, 0.05 M
NaCl, pH 5.5 buffer for 5 minutes. Cells were fixed and stained
with Hoescht 33342 and phalloidin 488. Cover slips were
mounted and imaged using a 63X objective with a Leica DMI
4000 B fluorescent microscope.
Wound healing assay
Cells were grown to 100% confluence overnight, then scratched
with a pipet tip to wound. Several marks were made along the
length of the wound, and were imaged over time, using these
marks as guides. Images were analyzed for wound length at the
same position over time using MetaXpress software.
Supporting Information
Text S1 Supplemental experimental procedures.
Found at: doi:10.1371/journal.ppat.1000954.s001 (0.09 MB PDF)
Figure S1 Vaccinia infection in Drosophila cells. A. Drosophila
DL1 cells were infected with vaccinia virus expressing B-gal driven
by an early/late promoter (p7.5) for indicated time, and stained for
X-gal production. A representative of 2 experiments is shown. B.
Titration of vaccinia infection in Drosophila cells seeded in 384 well
plates. Cells were fixed and processed 48 hpi and stained for early
B-gal expression (green) and nuclei (blue). C. Quantification of B.
Percent infection is the average of 6 wells, with 3 images per well
in duplicate experiments. Bars represent average percent infection
for each experiment.
Found at: doi:10.1371/journal.ppat.1000954.s002 (2.10 MB TIF)
Figure S2 Inhibitors of macropinocytosis inhibit vaccinia
infection in mammalian and Drosophila cells. A. Human U2OS
cells were pretreated with: Latrunculin A (Lat A, 5 mM),
Wortmannin (Wort, 5 mM), Rottlerin (10 mM), or EIPA
(12.5 mM) for 1 hour, challenged with vaccinia (MOI=10) for
8 hours, and quantified for percent infection. B. Drosophila DL1
cells were treated with: Latrunculin A (Lat A, 5 mM), Wortmannin
(Wort, 5 mM), and Rottlerin (5 mM), or EIPA (50 mM) for 1 hour
and challenged with vaccinia (MOI=20) for 24 hours. Cells were
fixed and processed for immunofluorescence using E3L expression
as a marker for infection, and Hoescht 33342 to visualize nuclei.
Mean percent infection + SD in triplicate experiments is shown; *
indicates p,0.05 compared to control in three independent
experiments.
Found at: doi:10.1371/journal.ppat.1000954.s003 (0.13 MB TIF)
Figure S3 Validation of eight candidates that promote vaccinia
infection identified in RNAi screen of Drosophila kinases and
phosphatases. Independent dsRNA targeting different sequences
of each candidate gene were tested, and percent infection was
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cells. Luciferase was used as a nontargeting negative control. B-gal
and Rab5 were added as positive controls for decreased infection.
A representative of duplicate experiments is shown. Error bars
represent standard deviation of 12 different wells with 3 images
taken per well. * indicate p-value of ,0.001 in both experiments.
Found at: doi:10.1371/journal.ppat.1000954.s004 (0.16 MB TIF)
Figure S4 dsRNA against AMPKa or LKB1 leads to depletion
of the cognate mRNA in Drosophila cells. RNAi was performed
against luciferase (luc) or AMPKa (A) or LKB1 (B)i nDrosophila
cells. RNA was collected from lysates and RT-PCR was performed
to measure mRNA levels. A 1:10 dilution of control cDNA (luc)
was included to demonstrate that the depletion was greater than
10-fold. Clathrin heavy chain (chc) was used as a loading control.
Found at: doi:10.1371/journal.ppat.1000954.s005 (1.75 MB TIF)
Figure S5 AMPKa1/AMPKa2
2/2 MEFs do not express
AMPKa. Wild type or AMPKa1/AMPKa2
2/2 MEF protein
lysates were collected and probed by immunoblot for total-
AMPKa and tubulin.
Found at: doi:10.1371/journal.ppat.1000954.s006 (0.26 MB TIF)
Figure S6 AMPK promotes efficient cowpox virus infection.
Plaque assays were performed on wild type or AMPKa1/
AMPKa2
2/2 MEFs and quantified in duplicate experiments.
Error bars show the individual values; * p,0.05 in each replicate.
Found at: doi:10.1371/journal.ppat.1000954.s007 (0.26 MB TIF)
Figure S7 AMPK is not required for Vesicular Stomatitis Virus
infection. Plaque assays were performed on wild type or
AMPKa1/AMPKa2
2/2 MEFs. There was no decrease in
plaque number observed in the mutant cells. A representative
experiment of three is shown.
Found at: doi:10.1371/journal.ppat.1000954.s008 (1.01 MB TIF)
Figure S8 AMPK promotes early vaccinia infection in mam-
malian cells. A. Lack of AMPKa leads to decreased vaccinia
infectivity in MEFs. Wild type or AMPKa1/AMPKa2
2/2 MEFs
were infected with the indicated MOI for 8 hours and processed
for immunofluorescence. Data is displayed as average percentage
of infected cells for a representative experiment. B. Loss of
AMPKa leads to a decrease in viral mRNA production in
AMPKa1/AMPKa2
2/2 MEFs. Northern blot of viral mRNA
levels in WT or AMPKa1/AMPKa2
2/2 MEFs at indicated
times post infection (MOI=10). Blots were probed for virally
encoded E3L or a ribosomal RNA loading control. C. Wild type
or AMPKa1/AMPKa2
2/2 cells were infected (MOI=10) for the
indicated times and probed for E3L by immunoblot.
Found at: doi:10.1371/journal.ppat.1000954.s009 (0.51 MB TIF)
Figure S9 siRNA targeting AMPK inhibits vaccinia infection in
mammalian cells. A. U2OS cells were treated with non-targeting
siRNA (siCON) or siRNA targeting AMPKa1 or AMPKa2 and
infected with vaccinia virus (MOI 10), and stained for E3L
expression after 8 hours. B. Quantification of percent infection
from A. The average of duplicate experiments; error bars
represent mean of the percent infection for each experiment. C.
Western blot probing total AMPKa after siRNA treatment.
Found at: doi:10.1371/journal.ppat.1000954.s010 (1.69 MB TIF)
Figure S10 LKB1 cDNA rescues the LKB1 null cells. LKB1
2/2
MEFs were complemented with a vector control (Vec) or FLAG-
LKB1 (LKB1) cDNA and were mock treated, or treated with 2-
deoxyglucose (2DG) which leads to LKB1-dependent AMPK
phosphorylation for 30 min. Protein lysates were collected and
probed by immunoblot for FLAG, phospho- or total-AMPKa
expression.
Found at: doi:10.1371/journal.ppat.1000954.s011 (0.72 MB TIF)
Figure S11 Vaccinia produced in AMPK deficient cells is
infectious. A. AMPK is not required for late vaccina protein
expression. WT and AMPKa1/AMPKa2
2/2 MEFs infected
with vaccinia for 8 hours were stained for early (E3L, green) and
late (L1R, red) vaccinia protein expression. B. Infectious virus is
produced in AMPK deficient cells. Vaccinia grown for 12 hours in
WT and AMPKa1/AMPKa2
2/2 MEFs was titered in BSC-1
cells. Rifampicin (Rif) was added as a control for detecting
incoming virus. The relative pfu/ml in BSC-1 cells was graphed as
the mean + standard deviation of triplicate experiments. The
decrease in virus produced was similar to decrease in virus entry.
Found at: doi:10.1371/journal.ppat.1000954.s012 (1.53 MB TIF)
Figure S12 AMPK deficient cells undergo efficient receptor-
mediated endocytosis. Transferrin uptake assays were performed
in the presence or absence of virus. Wild type and AMPKa1/
AMPKa2
2/2 MEFs were either infected or mock-infected and
treated with 594-transferrin (red), processed for microscopy, and
stained tovisualize actin (phalloidin (green)) and nuclei (Hoescht
33342 (blue)). Representative images from triplicate experiments
are shown.
Found at: doi:10.1371/journal.ppat.1000954.s013 (3.74 MB TIF)
Figure S13 AMPK deficient cells are defective in lamellipodia
formation during wound healing. A scratch was made in a
confluent monolayer of wild type or AMPKa1/AMPKa2
2/2
MEFs, and monitored over time. Images were taken using a 20X
and 63X objective immediately after wounding (T=0), and again
after 3 and 6 hours to determine the morphology of the cells at the
wound front. Polarized cells with lamellipodia are visible at the
wound front of wild type MEFs (arrows). Representative images
from triplicate experiments are shown.
Found at: doi:10.1371/journal.ppat.1000954.s014 (3.43 MB TIF)
Figure S14 Cellular motility is LKB1-independent. Scratches
were introduced into a confluent monolayer of LKB1
2/2, Vec or
LKB1
2/2; LKB1 cDNA MEFs, and monitored over time for
closure. Representative images from triplicate experiments are
shown immediately after wounding (T=0) and after 12 or
24 hours. The reduction in wound width is quantified over time.
Data are normalized to initial would width at T=0, and presented
as means of three independent experiments with four wounds per
set.
Found at: doi:10.1371/journal.ppat.1000954.s015 (3.01 MB TIF)
Table S1 Primary screen data.
Found at: doi:10.1371/journal.ppat.1000954.s016 (0.02 MB
TXT)
Video S1 Wild type MEFs were treated with 1 uM PMA and
imaged live at 10 second intervals for 30 minutes using DIC
microscopy. Extensive ruffling was observed at the cell periphery.
Found at: doi:10.1371/journal.ppat.1000954.s017 (12.77 MB
MOV)
Video S2 AMPKa1/AMPKa2
2/2 MEFs were treated with
1 uM PMA and imaged live at 10 second intervals for 30 minutes
using DIC microscopy. Cells remained quiescent and no ruffling
was observed.
Found at: doi:10.1371/journal.ppat.1000954.s018 (9.96 MB
MOV)
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